Search

Your search keyword '"Nadal, E."' showing total 63 results

Search Constraints

Start Over You searched for: Author "Nadal, E." Remove constraint Author: "Nadal, E." Publication Type Magazines Remove constraint Publication Type: Magazines
63 results on '"Nadal, E."'

Search Results

1. MA16.04 Circulating Tumor DNA Quantification by NGS Should Be Adapted to the Methodology Used

2. P1.27-07 BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy

5. 187P Tissue B-cell receptor repertoire as biomarker of complete pathological response in NSCLC patients treated with neoadjuvant chemoimmunotherapy (NADIM trials)

10. EP08.01-090 Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront

12. P2.07-02 RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC

13. OA02.03 Tumor Bulk-RNA Seq Identifies Patients at High Risk of Progression in Non-complete Pathological Responders from NADIM Trial

14. PL03.12 Progression Free Survival and Overall Survival in NADIM II Study

15. OA20.02 Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy

19. EP08.01-091 Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone +/- Chemotherapy Upfront

21. MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial

22. OA07.06 Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC)

23. Sobre la utilización de códigos de elementos finitos basados en mallados cartesianos en optimización estructural

24. P60.11 TCR Repertoire Predicts Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemoimmunotherapy from NADIM Trial

25. OA20.01 Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study

26. MA14.02 RET Fusion Testing in Advanced Non-Small Cell Lung Carcinoma Patients: the RETING Study

28. RELAY : étude de phase 3 internationale en double aveugle et randomisée comparant l’erlotinib (ERL) associé au ramucirumab (RAM) ou à un placebo (PL) comme traitement de première ligne chez des patients atteints d’un cancer bronchique non à petites cellules (CBNPC) métastatique avec une mutation du récepteur du facteur de croissance épidermique (EGFRm)

29. IBS06.01 Realtime Data from Europe ETOP / ESTS Database

31. Malignant transformation in IgM monoclonal gammopathy of undetermined significance

32. 81P Predictive molecular parameters of pneumonitis development in stage IIIa NSCLC patients treated with neo-adjuvant chemo-immunotherapy from NADIM clinical trial

33. The NH2-terminal extension of protein phosphatase PPZ1 has an essential functional role.

36. P60.07 TMB and Selected Mutations in Resectable Stage IIIA NSCLC Patients Receiving Neo-Adjuvant Chemo-Immunotherapy from NADIM Trial

37. Optimized Perforation Schemes in Railway Wheels Toward Acoustic Radiation Mitigation

38. OA13.05 NADIM Study: Updated Clinical Research and Outcomes

43. MA07.02 Early Change of dNLR Is Correlated with Outcomes in Advanced NSCLC Patients Treated with Immunotherapy

47. P2.04-10 Biomarkers of Pathological Response on Neo-Adjuvant Chemo-Immunotherapy Treatment for Resectable Stage IIIA NSCLC Patients

Catalog

Books, media, physical & digital resources